read-more
Read more about Fred Hutch achievements and accolades.
Dr. Philip Greenberg, head of the Program in Immunology at Fred Hutch, has been elected to serve on the board of directors of the American Association for Cancer Research. His term of service will last from 2017 to 2020.
He officially will begin his term April 1 at the AACR Annual Meeting 2017 in Washington, D.C.
“This is a time of explosive opportunities, but realizing this potential requires addressing several obstacles,” said Greenberg in an AACR statement. “I hope to establish platforms that promote cross-disciplinary interactions, including targeted scientific meetings and training opportunities for young scientists to gain experience in fields disparate from their primary training.”
Greenberg, a member of the Clinical Research Division at Fred Hutch, said he also plans to leverage his experience on legislative and public affairs committees for AACR and The American Association of Immunologists to enhance lobbying federal agencies and engage pharma and biotech in private/public relationships that support the research enterprise.
As co-editor-in-chief of Cancer Immunology Research, Greenberg also said he will apply his editorial experience to improve the process of disseminating scientific information.
Greenberg’s research focuses on immune cells called T cells. During his four decades at Fred Hutch, he has become a world expert in discovering how T cells can be manipulated to treat a range of cancers, often with milder side effects than traditional therapies.
